Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of 1,4-dihydro-1,6-naphthyridine derivative, pharmaceutical composition and use thereof

A technology of derivatives and compositions, applied in drug combinations, antipyretics, pharmaceutical formulations, etc., can solve problems such as limiting the use of MR antagonists

Active Publication Date: 2022-04-26
HUNAN NANXIN PHARMA CO LTD +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The risk of hyperkalemia currently limits the use of MR antagonists and excludes diabetics in particular

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of 1,4-dihydro-1,6-naphthyridine derivative, pharmaceutical composition and use thereof
  • A kind of 1,4-dihydro-1,6-naphthyridine derivative, pharmaceutical composition and use thereof
  • A kind of 1,4-dihydro-1,6-naphthyridine derivative, pharmaceutical composition and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6- The preparation of naphthyridine-4-deuterium-3-carboxamide (compound 1):

[0060]

[0061] Preparation of Intermediate 1-3: To a solution of methyl 3-oxobutyrate (10.0 g) in toluene (100 mL) were added 3-hydroxypropionitrile (16.4 g), NBS (5.0 g). The resulting suspension was stirred overnight at 120°C under nitrogen protection. TLC (petroleum ether:ethyl acetate=3:1) showed that the reaction was complete. Then water was added to quench the reaction, extracted with ethyl acetate, the organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. Purification by silica gel chromatography (petroleum ether: ethyl acetate = 3:1 elution) gave Intermediate 1-3 (5.0 g, 37.4% yield) as a yellow oily liquid. MS(ESI):m / z 156.06[M+1] + ; 1 H NMR (400MHz, CDCl3) δ 2.30 (s, 3H), 2.74-2.76 (m, 2H), 3.54 (s, 2H), 4.34-4.38 (m, 2H). Preparation of ...

Embodiment 2

[0069] Example 2: (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2-methyl-8-trideuteromethyl-1,4-dihydro The preparation of -1,6-naphthyridine-4-hydrogen-3-carboxamide (compound 2):

[0070]

[0071] Preparation of Intermediate 2-1: Pyridine (16 g, 200 mmol) was added to lithium hexamethyldisilazide (1M THF solution, 205 mL), cooled to 0°C, and stirred for 40 min. Trideuteriodomethane (30g, 405mmol) was added dropwise. After the dropwise addition, the temperature was increased to 30°C, reacted for 5h, cooled to 0°C, and saturated ammonium chloride solution was used to quench the reaction. The aqueous phase was extracted three times with ethyl acetate, acetic acid The ethyl ester phase was combined with the organic phase, dried over anhydrous sodium sulfate, and the filtrate was concentrated in vacuo. Intermediate 2-1 was obtained as a white solid (14.4 g, yield 75%) by silica gel chromatography (PE:ethyl acetate=1:2). LCMS:m / z 97.02[M+H] + .

[0072] Preparation of Intermedia...

Embodiment 3

[0080] The preparation of compound 2: compound 2-11 (150mg), is resolved by following method with SFC: operating system: WatersUPCC (CA-119) supercritical fluid chromatography; Chromatographic column: AS-3 (100*3mm 3μm); mobile phase A: supercritical carbon dioxide; mobile phase B: methanol (0.1% diethylamine); flow rate: 1.5mL / min. SFC resolution showed that there were two peaks, peak 1 corresponding to 3.488min (R) body compound white solid (70mg, 99% purity), peak 2 corresponding to 4.915min (S) body (76mg, 99.4% purity) The white solid is compound 2. LCMS:m / z 382.2[M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ1.03-1.07 (m, 3H), 2.19 (s, 3H), 3.82 (s, 3H), 4.00-4.02 (m, 2H), 5.57 (s, 3H), 6.67-6.74 (m, 2H), 7.15 (d, J=8Hz, 1H), 7.26-7.29 (m, 1H), 7.37 (s, 1H), 7.55 (s, 1H), 7.69 (s, 1H). Example 3: (S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2-methyl-8-trideuteromethyl-1,4-dihydro Preparation of -1,6-naphthyridine-4-deuterium-3-carboxamide (compound 3):

[0081]

[0082] Prep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
electrical resistanceaaaaaaaaaa
electrical resistanceaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a 1,4-dihydro-1,6-naphthyridine derivative, a pharmaceutical composition and its use, and also relates to the application of it and its pharmaceutical composition for the treatment and prevention of cardiovascular, metabolic and kidney-related diseases purposes, the invention belongs to the field of medicine.

Description

[0001] field of invention [0002] The invention belongs to the technical field of medicine, and in particular relates to a 1,4-dihydro-1,6-naphthyridine derivative, a pharmaceutical composition and an application thereof. More specifically, the present invention relates to methods for the preparation of said compounds, pharmaceutical compositions containing them and mineralocorticoid (MR) receptor modulators using them to improve vascular function, relating to their potential therapeutic and / or prophylactic Use in clinical conditions including cardiovascular and metabolic diseases, such as hypertension, heart failure, chronic kidney disease, diabetic nephropathy, fibrosis, endothelial dysfunction and muscle atrophy, and methods for their potential therapeutic use, involving Pharmaceutical compositions comprising them and to processes for the preparation of these compounds. Background technique [0003] The mineralocorticoid receptor (MR) is a member of the steroid receptor f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04A61K31/4375A61P3/00A61P9/00A61P9/12A61P9/04A61P13/12A61P3/10A61P21/00A61P9/08A61P3/06A61P7/02A61P29/00
CPCC07D471/04A61P3/00A61P9/00A61P9/12A61P9/04A61P13/12A61P3/10A61P21/00A61P9/08A61P3/06A61P7/02A61P29/00C07B2200/07
Inventor 王永钢林寨伟廖辉陈海杰崔柏成胡双华
Owner HUNAN NANXIN PHARMA CO LTD